Identifying Hypoxic Tumors for Improved Cancer Treatment
Selecting Hypoxic Tumours for Treatment Modification
This study is testing a way to find tumors with low oxygen levels in bladder and prostate cancer patients to see if personalizing their treatment can help them respond better to radiotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Manchester Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Manchester) |
| Trial ID | NCT06787053 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify hypoxic tumors in patients with bladder and prostate cancer to personalize treatment and improve outcomes. Hypoxic tumors, which have low oxygen levels, often respond poorly to radiotherapy, but can benefit from intensified treatment strategies. The study utilizes gene-expression signature-based biomarkers derived from archived tumor tissue to identify patients with hypoxic tumors, potentially leading to better therapeutic responses. The research is conducted at The Christie NHS Foundation Trust in Manchester, focusing on patients undergoing radiotherapy.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with bladder or prostate cancer who are undergoing radiotherapy and can tolerate MRI imaging.
Not a fit: Patients who are unable to undergo MRI scans or have contraindications to MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance treatment efficacy for patients with hypoxic tumors, leading to improved cancer outcomes.
How similar studies have performed: Other studies have shown promise in using gene-expression signatures to identify hypoxic tumors, suggesting a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: This will be tumour site dependent. Bladder: * Older than age 18 years. * Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner. * Able to give informed consent. Cervix: * Older than age 18 years. * Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner. * Able to give informed consent. Prostate: * Older than age 18 years. * Patients having radiotherapy at the Christie NHS Foundation Trust suitable for imaging on an MRI scanner. * Able to give informed consent. Exclusion Criteria: This will be tumour site dependent Bladder: * Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form. * Unable to tolerate MRI scans. * Pregnancy. Cervix: * Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form. * Unable to tolerate MRI scans. * Pregnancy. Prostate: * Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form. * Unable to tolerate MRI scans
Where this trial is running
Manchester
- The Christie NHS Foundation Trust — Manchester, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Ananya Choudhury, Professor — University of Manchester
- Study coordinator: Rachel Reed, MSc
- Email: rachel.reed@manchester.ac.uk
- Phone: 01619184780
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.